Cai Li, Uchiyama Hachiro, Yanagisawa Shinichiro, Kamae Isao
Department of Sociomedical Infomatics, Division of Applied Medical Statistics and Decision Sciences, Kobe University Graduate School of Medicine, Kobe, Japan.
Kobe J Med Sci. 2006;52(3-4):97-109.
During the periods of seasonal flu in 2003 and 2004, it was found that about 45 percent of elderly people in Japan had been inoculated with influenza vaccines. Comparatively, however, the proportion of inoculation with pneumococcal vaccine was only 0.1 percent. Taking into account such incongruent proportions, this study assesses health and economic benefits of vaccination strategies for both influenza and pneumonia particularly for the elderly population in Japan. To accomplish this objective, a cost-effectiveness analysis was conducted with the use of the Monte Carlo simulation based on the data from medical literature as well as from the public organizations, wherein three strategic patterns were delineated and compared (i) no vaccination (ii) influenza vaccine only, and (iii) combined influenza with pneumococcal vaccines. The cost for one year of life saved by each strategy was compared with the scenario of no vaccinations. It was found that for 100,000 elderly people over 65 years of age in Japan, the cost-effectiveness ratio of influenza-only vaccination was 516,332 Japanese yen per one year of life saved, while the combined vaccinations of influenza with pneumococcal was 459,874 Japanese yen for the same benefit. The incremental cost-effectiveness ratio of the strategies (iii) versus (ii) was 426,698 Japanese yen per one year of life saved for 100,000 people. Consequently it was indicated that the combined vaccinations would be more cost-effective than the vaccination for influenza only.
在2003年和2004年季节性流感期间,发现日本约45%的老年人接种了流感疫苗。然而,相比之下,肺炎球菌疫苗的接种比例仅为0.1%。考虑到这种不协调的比例,本研究评估了流感和肺炎疫苗接种策略对健康和经济的益处,特别是对日本老年人群体。为实现这一目标,基于医学文献以及公共组织的数据,利用蒙特卡洛模拟进行了成本效益分析,其中划定并比较了三种战略模式:(i) 不接种疫苗;(ii) 仅接种流感疫苗;(iii) 联合接种流感疫苗和肺炎球菌疫苗。将每种策略挽救一年生命的成本与不接种疫苗的情况进行了比较。结果发现,对于日本10万名65岁以上的老年人,仅接种流感疫苗的成本效益比为每挽救一年生命516,332日元,而联合接种流感疫苗和肺炎球菌疫苗的成本效益比为每获得相同效益459,874日元。对于10万人而言,策略(iii) 相对于策略(ii) 的增量成本效益比为每挽救一年生命426,698日元。因此,表明联合接种疫苗比仅接种流感疫苗更具成本效益。